Inspiratory flow rates at different levels of resistance in elderly COPD patients.
about
Epidemiology and management of common pulmonary diseases in older personsInvestigating the relationship between peak inspiratory flow rate and volume of inhalation from a Diskus™ Inhaler and baseline spirometric parameters: a cross-sectional study.Concept review of dry powder inhalers: correct interpretation of published data.Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment optionsRecent advances in capsule-based dry powder inhaler technology.Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers?Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary diseaseDry powder inhalers and the right things to remember: a concept review.Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium.The challenge of delivering therapeutic aerosols to asthma patientsExacerbation rate, health status and mortality in COPD--a review of potential interventionsBeclomethasone/formoterol fixed combination for the management of asthma: patient considerations.Considerations for managing chronic obstructive pulmonary disease in the elderlyCustomizing inhaled therapy to meet the needs of COPD patients.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: not simple math.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.Dry powder inhalers in COPD, lung inflammation and pulmonary infections.Industry guidance for the selection of a delivery system for the development of novel respiratory products.The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD ExacerbationSuboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions.Inhalation of tobramycin using simulated cystic fibrosis patient profiles.Personalization of Device Therapy - Prime Time for Peak Inspiratory Flow Rate.Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases.Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
P2860
Q28397465-938A5836-1D6D-4986-B046-15E9A0CEE7FCQ30429458-449F3C0B-2FF6-4B33-AD60-EF8C0D44E59FQ31030099-CA09F090-7C95-4A1D-B6E3-48C87006888EQ33644839-E2953999-8068-4BF3-A309-53B66D1ABB4CQ33711473-A57388BE-3FF8-456D-B0E9-79F0D48B4A13Q34065987-311BF934-8293-46E9-BC3C-8C90C166B6D0Q34156985-BC668744-67DF-4ECE-87D0-84CB3EF99CC2Q34247921-C1807CCD-2C9F-425A-B6D9-1BCC51E1A233Q35096988-F1B8CDD4-0A3C-4DD7-A73C-15DC96636D47Q35268320-E0877A93-38D0-4982-A72B-31C664E818A6Q35426748-60A0C724-F93A-47BE-A406-296626A2864BQ36388416-23E2E499-80FE-4937-B211-192AF8CE94C2Q37077219-FE0D1726-5E79-4DD7-9DDF-9DB7CF78155AQ37105708-A2643F3D-E549-4C3E-863B-912D448E574DQ37236165-5D2663F8-39D5-4A64-80AF-447D64DA36A2Q37390386-E68EDF86-78E3-44E0-A760-5BDA9298BE55Q37396797-16C2A72F-0060-4C92-87DE-DACF98FCA085Q37702735-FFE3EEDD-576B-4F7D-B160-6F1AF5E6C68CQ37804908-0053B6C1-EC09-4174-A40C-0595168772C7Q38057220-F30862F0-85BD-4D15-BD4D-EFBC7D9273C7Q38066413-092BAA06-FBB4-4A05-9DCD-8546E9894E32Q38131050-F02A1014-A029-434F-8685-5900D7B899DFQ38193172-0B3E5031-AB95-481C-B1AC-9D506AA9B595Q38248438-91280B3A-05FC-4AF1-A34E-34C244343E28Q38267333-7728CDB7-90D3-4F0E-96EB-CA1E01ABF037Q38525610-F234AB00-E826-4AAD-83B9-C6EBDCC46DFBQ38598993-99CBCE09-F887-455E-98DE-6BC630BE76DDQ38604589-4B171073-1C86-48F4-88F5-E9BC66E30AF4Q38838497-CCC09EA1-AA68-49D9-A0E6-6353F272C2CBQ40505534-7FDD8DB8-55D3-4BB0-9686-35B59CC54ED6Q41401371-31E4C464-5726-46E2-BC5A-CCEA9F5F4CF0Q41441617-ECAD640D-73FC-46F1-8835-22E47EA81C26Q42319679-B5E0E359-E963-4B16-B879-C4D91EA51465Q47652466-01034067-9776-4325-B46E-D5C0A4C64646
P2860
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
@en
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
@nl
type
label
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
@en
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
@nl
prefLabel
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
@en
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
@nl
P2093
P1476
Inspiratory flow rates at different levels of resistance in elderly COPD patients.
@en
P2093
E De Langhe
E Hardeman
M Decramer
P VandenBrande
T Troosters
W Janssens
P356
10.1183/09031936.00024807
P577
2007-09-26T00:00:00Z